TG Therapeutics, Inc.
TGTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $5,281,173 | $5,783,505 | $4,374,042 |
| - Cash | – | $129,126 | $132,139 | $179,894 |
| + Debt | – | $253,716 | $254,583 | $254,380 |
| Enterprise Value | – | $5,405,763 | $5,905,949 | $4,448,528 |
| Revenue | $161,709 | $141,148 | $120,856 | $108,185 |
| % Growth | 14.6% | 16.8% | 11.7% | – |
| Gross Profit | $133,554 | $122,210 | $105,315 | $92,786 |
| % Margin | 82.6% | 86.6% | 87.1% | 85.8% |
| EBITDA | $32,692 | $37,695 | $12,281 | $32,576 |
| % Margin | 20.2% | 26.7% | 10.2% | 30.1% |
| Net Income | $390,895 | $28,187 | $5,060 | $23,331 |
| % Margin | 241.7% | 20% | 4.2% | 21.6% |
| EPS Diluted | 2.428 | 0.17 | 0.031 | 0.15 |
| % Growth | 1,328.2% | 446.6% | -79.3% | – |
| Operating Cash Flow | – | $7,436 | -$28,715 | -$25,641 |
| Capital Expenditures | – | -$42 | -$25 | -$21 |
| Free Cash Flow | – | $7,394 | -$28,740 | -$25,662 |